Long-term use of ticagrelor in patients with prior myocardial infarction [5]

New England Journal of Medicine

Volumn 373, Issue 13, 2015, Pages 1274-

  Flather, Marcus ^a   Bakhai, Ameet ^b   De Arenaza, Diego Perez ^c  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT;

BLEEDING RISK; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HEALTH CARE POLICY; HEART INFARCTION; HUMAN; LETTER; LONG TERM CARE; PRIORITY JOURNAL; REGISTER; RISK; THROMBOCYTE FUNCTION; ANALOGS AND DERIVATIVES; FEMALE; MALE; MYOCARDIAL INFARCTION;

ADENOSINE; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS;

EID: 84942420844     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1508692     Document Type: Letter

References (3)

1. Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006;333:1091.
2. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011;57:173-80.
3. Cuisset T, Grosdidier C, Loundou AD, et al. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (Predictor of Bleedings with Antiplatelet Drugs). JACC Cardiovasc Interv 2013;6: 854-63.